Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of Concomitant Traumatic Abdominal Vascular and Gastrointestinal Injuries: A Descriptive Study.

The Journal of surgical research·2026

Same author

Reducing Unnecessary Medical Screening for Pediatric Psychiatric Admissions in the Emergency Department: A Quality Improvement Approach to Implementing Choosing Wisely Recommendations.

Journal of the American Academy of Child and Adolescent Psychiatry·2026

Same author

Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis.

Neurology and therapy·2026

Same author

HIV-1 infection induces Vif-mediated SUMOylation of host RNA splicing factors important for proper viral RNA splicing.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Validation of a safe volumetric cut-off for observation of traumatic hemothorax: A Western Trauma Association multicenter study.

The journal of trauma and acute care surgery·2026

Same author

Post-intensive Care Syndrome (PICS): an American Association for the Surgery of Trauma Critical Care Committee Consensus Guideline - Defining, Recognizing, and Managing PICS Associated Physical Impairment, Cognitive Dysfunction, and Thromboinflammatory Dysregulation.

Trauma surgery & acute care open·2026

Same journal

Endothelial Cell Phenotypic Plasticity in Atherosclerosis.

Handbook of experimental pharmacology·2026

Same journal

Endothelial Dysfunction and Neurovascular Alterations in Autism Spectrum Disorder.

Handbook of experimental pharmacology·2026

Same journal

Molecular Mechanisms of Endothelial Shear Stress Mechanotransduction in Health and Disease.

Handbook of experimental pharmacology·2026

Same journal

Microvasculature of the Pancreatic Islets of Langerhans in Health and Diabetes.

Handbook of experimental pharmacology·2026

Same journal

Mechanisms of Actions of Physiological, Pharmacological, and Toxicological Dietary Bioactive Inorganic Boron.

Handbook of experimental pharmacology·2026

Same journal

BNCT Plus Luminescence: New Paradigm for Boron-Containing Drug Design.

Handbook of experimental pharmacology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Viral protease inhibitors.

Jeffrey Anderson¹, Celia Schiffer, Sook-Kyung Lee

¹Division of Infectious Diseases, Department of Internal Medicine, University of Massachusetts, Worcester, MA, USA.

Handbook of Experimental Pharmacology

|December 3, 2008

Summary

This summary is machine-generated.

Viral protease inhibitors, particularly for HIV-1, show significant advances. This review covers their development, clinical use, resistance, and potential for other viruses like HCV, Dengue, and coronaviruses.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 27, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

Virology
Drug Development
Biochemistry

Background:

Viral proteases are essential enzymes for viral replication.
Inhibitors targeting these proteases represent a key strategy in antiviral drug development.
Significant progress has been made in developing inhibitors for Human Immunodeficiency Virus type 1 (HIV-1).

Purpose of the Study:

To review the development of viral protease inhibitors as antiviral therapeutics.
To focus on HIV-1 protease inhibitors, including their biochemistry, development, clinical use, and resistance.
To explore the potential for developing protease inhibitors for other significant viral targets.

Main Methods:

Literature review and synthesis of existing research on viral protease inhibitors.
Analysis of the biochemical mechanisms of viral proteases and inhibitor interactions.
Examination of clinical data, resistance patterns, and future therapeutic directions.

Main Results:

HIV-1 protease inhibitors have advanced significantly, impacting treatment paradigms.
Hepatitis C virus (HCV) NS3/4A serine protease inhibitors are also well-developed, with combination therapies showing promise.
Other viral proteases (Dengue, CMV, Rhinovirus, Coronavirus) are identified as potential targets for future inhibitor development.

Conclusions:

Protease inhibitors are a viable and effective class of antiviral drugs.
The success with HIV-1 and HCV validates protease inhibition as a therapeutic strategy.
Further research into diverse viral proteases could yield new treatments for a range of viral infections.